{
    "clinical_study": {
        "@rank": "38395", 
        "arm_group": [
            {
                "arm_group_label": "BCD-022 (CISC BIOCAD)", 
                "arm_group_type": "Experimental", 
                "description": "BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BCD-022 at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations)."
            }, 
            {
                "arm_group_label": "Herceptin \u00ae (F. Hoffmann-La Roche Ltd., Switzerland)", 
                "arm_group_type": "Active Comparator", 
                "description": "In this arm patients will receive 6 courses of treatment with Herceptin in combination with paclitaxel. Patients will receive Herceptin at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations)."
            }
        ], 
        "brief_summary": {
            "textblock": "BCD-022-02 is a double-blind randomized clinical trial comparing efficacy of BCD-022 (INN:\n      trastuzumab) and paclitaxel to Herceptin and paclitaxel in HER2-positive metastatic breast\n      cancer with pharmacokinetics substudy. The purpose of the study is to demonstrate the\n      non-inferiority of efficacy and safety of BCD-022 compared to Herceptin. Also study includes\n      pharmacokinetics assessment."
        }, 
        "brief_title": "A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2-Positive Metastatic Breast Cancer Patients", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "HER2-positive Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent and ability to follow the Protocol procedures;\n\n          -  Age from 18 years to 70 years inclusive;\n\n          -  Female gender;\n\n          -  Histologically confirmed breast cancer (BC);\n\n          -  Metastatic BC (stage IV according to TNM classification version 6);\n\n          -  Grade 3+ HER2 overexpression confirmed by immunohistochemical (IHC) staining or grade\n             2+ HER2 overexpression accompanied by HER2 gene amplification confirmed by\n             fluorescent hybridization in situ (FISH) ;\n\n          -  Documented results of oestrogen and progesterone receptors expression analysis;\n\n          -  Eastern Cooperative Oncology Group (ECOG) status 0, 1 or 2, not increasing within 2\n             weeks prior to randomization;\n\n          -  Life expectancy - 20 weeks or more from the moment of randomization;\n\n          -  Presence of at least 1 tumour with a size not less than 1 cm (revealed with computed\n             tomography (CT) slice thickness not more than 5 mm). Patients having bone metastasis\n             as the only measurable tumour are not eligible for the trial;\n\n          -  Patients of childbearing potential  must implement reliable contraceptive measures\n             during the study treatment, starting 4 weeks prior to inclusion into the trial and\n             until 6 months after the last administration of the study drug.\n\n        Exclusion Criteria:\n\n          -  Previous anticancer therapy for metastatic BC, including cytotoxic chemotherapy, or\n             previous anticancer therapy with signal transduction inhibitors (e.g. lapatinib),\n             biological drugs (e.g. trastuzumab, bevacizumab), experimental (not approved for BC\n             therapy) anticancer drugs. Any previous hormonal therapy is allowed;\n\n          -  Disease progression within 6 months after adjuvant and/or neoadjuvant anti BC\n             therapy;\n\n          -  Surgery, radiation therapy, use of any experimental medications within 14 weeks prior\n             to randomization;\n\n          -  Hypersensitivity to paclitaxel and all medications containing polyoxyethylated castor\n             oil, hypersensitivity to dexamethasone, diphenhydramine, ranitidine/cimetidine,\n             recombinant murine proteins, contrast agents or excipients of study medications;\n\n          -  BC metastases in central nervous system, progressing or clinically manifested (e.g.\n             cerebral oedema, spinal cord injury), with exception of non-progressing metastases\n             not requiring treatment with glucocorticosteroids and/or anticonvulsants within 4\n             weeks prior to randomization;\n\n          -  Cardiovascular system pathology (congestive heart failure (CHF) stage III-IV\n             according to New York Heart Association (NYHA) classification, unstable angina\n             pectoris, myocardial infarction) within 12 months prior to randomization;\n\n          -  Uncontrolled hypertension comprising all cases of arterial hypertension when no\n             decrease in blood pressure could be achieved despite treatment with a combination of\n             3 antihypertensive drugs including one diuretic and non-medicamental correction\n             methods (low salt diet, physical exercise);\n\n          -  Left ventricular ejection fraction <50% according to electrocardiography;\n\n          -  Neutrophils \u22641500/mm3;\n\n          -  Platelets \u2264100 000/mm3;\n\n          -  Hemoglobin \u226490 g/L;\n\n          -  Creatinine level \u2265 1.5 \u00d7 upper limit of normal (ULN);\n\n          -  Bilirubin level \u2265 1.5 \u00d7 ULN;\n\n          -  Asparagine transferase (AST) and  alanine transferase (ALT) levels \u2265 2.5 \u00d7 ULN (5 \u00d7\n             ULN for patients with liver metastases);\n\n          -  Alkaline phosphatase level \u2265 5 \u00d7 ULN;\n\n          -  Pregnancy or lactation;\n\n          -  Any other concomitant cancer including contralateral breast cancer revealed within 5\n             years prior to screening, except curatively treated intraductal carcinoma in situ,\n             curatively treated cervical carcinoma in situ or curatively treated basal cell or\n             squamous cell carcinoma;\n\n          -  Conditions limiting patient's adherence to protocol requirements (dementia,\n             neurologic or psychiatric disorders, drug addiction, alcoholism and others);\n\n          -  Stage II-IV neuropathy according to Common Terminology Criteria for Adverse Events\n             (CTCAE) v.4.0;\n\n          -  Concomitant participation in other clinical trials, previous participation in other\n             clinical trials within 30 days before entering into the trial, previous participation\n             in the same trial;\n\n          -  Acute or active chronic infections;\n\n          -  Hepatitis C virus, hepatitis B virus, HIV or syphilis infections;\n\n          -  Obstacles in intravenous administration of study drugs"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "206", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764022", 
            "org_study_id": "BCD-022-02"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BCD-022 (CISC BIOCAD)", 
                    "Herceptin \u00ae (F. Hoffmann-La Roche Ltd., Switzerland)"
                ], 
                "description": "Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).", 
                "intervention_name": "Trastuzumab", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BCD-022", 
                    "Herceptin"
                ]
            }, 
            {
                "arm_group_label": [
                    "BCD-022 (CISC BIOCAD)", 
                    "Herceptin \u00ae (F. Hoffmann-La Roche Ltd., Switzerland)"
                ], 
                "description": "Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxacad"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Paclitaxel", 
                "Trastuzumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "breast cancer", 
            "trastuzumab"
        ], 
        "lastchanged_date": "January 10, 2014", 
        "link": {
            "url": "http://www.biocad.ru"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brest", 
                        "country": "Belarus"
                    }, 
                    "name": "Brest Region Clinical Oncology Dispensary"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gomel", 
                        "country": "Belarus"
                    }, 
                    "name": "Gomel Region Clinical Oncology Dispensary"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grodno", 
                        "country": "Belarus"
                    }, 
                    "name": "Grodno Regional Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vitebsk", 
                        "country": "Belarus"
                    }, 
                    "name": "Vitebsk State Medical University of Order of Peoples' Friendship"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India", 
                        "zip": "560027"
                    }, 
                    "name": "HCG Bangalore Institute of Oncology"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India", 
                        "zip": "560099"
                    }, 
                    "name": "Narayana Hrudayalaya Hospitals"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India", 
                        "zip": "560054"
                    }, 
                    "name": "M.S.Ramaiah Memorial Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stepanovskoye", 
                        "country": "Russian Federation", 
                        "state": "Moscow Region", 
                        "zip": "143423"
                    }, 
                    "name": "State Health Institution of Moscow \"Moscow City Oncology Hospital #62 of Moscow Board of Health\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arkhangelsk", 
                        "country": "Russian Federation", 
                        "zip": "163045"
                    }, 
                    "name": "Arkhangelsk District Clinical Oncology Dispensary"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chelyabinsk", 
                        "country": "Russian Federation", 
                        "zip": "355047"
                    }, 
                    "name": "Non-governmental Healthcare Institution \"Railway Clinical hospital on the Chelyabinsk Station of JSC Russian Railways\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chelyabinsk", 
                        "country": "Russian Federation", 
                        "zip": "454087"
                    }, 
                    "name": "State-financed Health Institution \"Chelyabinsk Region Clinical Oncology Dispansary\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Izhevsk", 
                        "country": "Russian Federation", 
                        "zip": "426009"
                    }, 
                    "name": "State-financed Health Institution \"Republican Clinical Oncology Hospital\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "125284"
                    }, 
                    "name": "Federal State Institution \"Moscow Institute of Cancer Research named after P.A. Hertsen\" Ministry of Health of Russian Federation"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "115478"
                    }, 
                    "name": "Institution of Russian Academy of Medical Sciences \"Russian Cancer Research Center named after N.N. Blokhin\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orel", 
                        "country": "Russian Federation", 
                        "zip": "302020"
                    }, 
                    "name": "Regional State Health Institution \"Orlov Oncology Dispansary\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Penza", 
                        "country": "Russian Federation", 
                        "zip": "440071"
                    }, 
                    "name": "State Health Institution \"Region Oncology Dispansary\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perm", 
                        "country": "Russian Federation", 
                        "zip": "614066"
                    }, 
                    "name": "Perm Region Oncology Dispensary"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rostov-on-Don", 
                        "country": "Russian Federation", 
                        "zip": "314019"
                    }, 
                    "name": "Federal Government Budgetary Institution \"Rostov Institute of Cancer Research\" of Ministry of Health of Russian Federation"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "197022"
                    }, 
                    "name": "Saint Petersburg City Clinical Oncology Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Samara", 
                        "country": "Russian Federation", 
                        "zip": "443031"
                    }, 
                    "name": "State-financed Health Institution \"Samara Region Clinical Oncology Dispansary\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sochi", 
                        "country": "Russian Federation", 
                        "zip": "354057"
                    }, 
                    "name": "Oncology Dispensary 2"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St.Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "197758"
                    }, 
                    "name": "N.N.Petrov Oncology Research Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St.Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "194044"
                    }, 
                    "name": "Military Medical Academy named after S.M. Kirov"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St.Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Russian scientific center of radiology and surgery technologies"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stavropol", 
                        "country": "Russian Federation", 
                        "zip": "355047"
                    }, 
                    "name": "State-financed Health Institution \"Stavropol Region Clinical Oncology Dispansary\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ufa", 
                        "country": "Russian Federation", 
                        "zip": "450054"
                    }, 
                    "name": "Republican Clinical Oncology Dispensary of Ministry of Health republic Bashkortostan"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Volgograd", 
                        "country": "Russian Federation", 
                        "zip": "400138"
                    }, 
                    "name": "Volgograd District Oncology Dispensary \u21161"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Donetsk", 
                        "country": "Ukraine"
                    }, 
                    "name": "Donetsk City Oncology Dispensary"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Donetsk", 
                        "country": "Ukraine"
                    }, 
                    "name": "Donetsk Regional Antitumor Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kharkiv", 
                        "country": "Ukraine"
                    }, 
                    "name": "Kharkiv Regional Clinical Oncology Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kryvyi Rih", 
                        "country": "Ukraine"
                    }, 
                    "name": "Kryvyi Rih Oncology Dispensary"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lviv", 
                        "country": "Ukraine"
                    }, 
                    "name": "Lviv Regional State Cancer Diagnostics and Treatment Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Makiivka", 
                        "country": "Ukraine"
                    }, 
                    "name": "City Hospital \u21162"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poltava", 
                        "country": "Ukraine"
                    }, 
                    "name": "Poltava Regional Clinical Oncology Dispensary"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uzhhorod", 
                        "country": "Ukraine"
                    }, 
                    "name": "Zakarpatskyi Regional Clinical Oncology Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vinnytsia", 
                        "country": "Ukraine"
                    }, 
                    "name": "Vinnytsia Regional Clinical Oncology Dispensary"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belarus", 
                "India", 
                "Russian Federation", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "International Multicenter Randomized Double Blind Phase III Clinical Trial Comparing Safety and Efficacy of BCD-022 (CJSC BIOCAD, Russia) Used With Paclitaxel to Herceptin\u00ae (F. Hoffmann-La Roche Ltd, Switzerland) Used With Paclitaxel in the First-line Treatment of HER2-positive Metastatic Breast Cancer Patients", 
        "overall_contact": {
            "email": "biryulin@biocad.ru", 
            "last_name": "Andrey Biryulin, MD", 
            "phone": "+7 (812) 380-49-33", 
            "phone_ext": "925"
        }, 
        "overall_contact_backup": {
            "email": "filonov@biocad.ru", 
            "last_name": "Olga Filon, MD", 
            "phone": "+7 (812) 380-49-33", 
            "phone_ext": "916"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "primary outcome measure for efficacy evaluation", 
                "measure": "Overall response rate", 
                "safety_issue": "No", 
                "time_frame": "Day 127"
            }, 
            {
                "description": "primary outcome measure for pharmacokinetics (PK) substudy", 
                "measure": "Area under the curve after the first test drug administration", 
                "safety_issue": "No", 
                "time_frame": "up to Day 22, after the first trastuzumab administration (time points for blood samples: 0 h 1.5 h, 3 h, 4.5 h, 6 h, 24 h, 96 h, 168 h, 336 h and 504 h)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764022"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "secondary outcome measure for efficacy evaluation", 
                "measure": "Complete response rate", 
                "safety_issue": "No", 
                "time_frame": "Day 127"
            }, 
            {
                "description": "secondary outcome measure for efficacy evaluation", 
                "measure": "Partial response rate", 
                "safety_issue": "No", 
                "time_frame": "Day 127"
            }, 
            {
                "description": "secondary outcome measure for efficacy evaluation", 
                "measure": "Stabilization rate", 
                "safety_issue": "No", 
                "time_frame": "Day 127"
            }, 
            {
                "description": "secondary outcome measure for efficacy evaluation", 
                "measure": "Progression rate", 
                "safety_issue": "No", 
                "time_frame": "Day 127"
            }, 
            {
                "description": "secondary outcome measure for safety evaluation", 
                "measure": "Relative number (%) of chemotherapy cycles, postponed due to adverse events (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 127"
            }, 
            {
                "description": "secondary outcome measure for safety evaluation", 
                "measure": "Treatment discontinuation rate due to AE", 
                "safety_issue": "Yes", 
                "time_frame": "Day 127"
            }, 
            {
                "description": "secondary outcome measure for safety evaluation", 
                "measure": "AE incidence and severity", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 148"
            }, 
            {
                "description": "secondary outcome measure for safety evaluation", 
                "measure": "AEs grade 3-4 incidence", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 148"
            }, 
            {
                "description": "Secondary outcome measure for immunogenicity assessment", 
                "measure": "Occurrence and titer of anti-trastuzumab antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 (before the drug administration), Day 15, 64 and 127"
            }, 
            {
                "description": "secondary outcome measure for PK substudy", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 22"
            }, 
            {
                "description": "secondary outcome measure for PK substudy", 
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 22"
            }, 
            {
                "description": "secondary outcome measure for PK substudy", 
                "measure": "T1/2", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 22"
            }, 
            {
                "description": "Secondary outcome measure for pharmacokinetics analysis", 
                "measure": "minimal serum trastuzumab concentration", 
                "safety_issue": "No", 
                "time_frame": "Day 22, Day 43, Day 64, Day 85, Day 106, Day 127"
            }
        ], 
        "source": "Biocad", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biocad", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}